Relmada Therapeutics, Inc. (RLMD) Financial Statements (2024 and earlier)

Company Profile

Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR
CORAL GABLES, FL 33134
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
6/30/2019
6/30/2018
6/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments148,323211,910117,0919,2172,2391,711
Cash and cash equivalents5,39644,4432,4959,2172,2391,711
Short-term investments142,927167,466114,596   
Receivables 512 7924772292
Prepaid expense4,03511,302903521427472
Other undisclosed current assets  86    
Total current assets:152,870223,298118,0749,9842,7382,475
Noncurrent Assets
Nontrade receivables   86203273338
Property, plant and equipment   17122
Other noncurrent assets352825252522
Total noncurrent assets:3528113235310362
TOTAL ASSETS:152,905223,326118,18610,2203,0482,837
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,46915,06112,6032,2421,425924
Accounts payable5,26211,1938,346924765530
Accrued liabilities7,2073,8684,2571,318659395
Debt    364285277
Derivative instruments and hedges, liabilities     4,195176
Total current liabilities:12,46915,06112,6032,6065,9051,377
Noncurrent Liabilities
Long-term debt and lease obligation     2,656 
Long-term debt, excluding current maturities     2,656 
Total noncurrent liabilities:     2,656 
Total liabilities:12,46915,06112,6032,6068,5611,377
Equity
Equity, attributable to parent140,436208,265105,5837,613(5,513)1,460
Common stock302816391313
Additional paid in capital602,517513,304284,882119,23788,81986,831
Accumulated deficit(462,111)(305,067)(179,315)(111,662)(94,344)(85,383)
Total equity:140,436208,265105,5837,613(5,513)1,460
TOTAL LIABILITIES AND EQUITY:152,905223,326118,18610,2203,0482,837

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
6/30/2019
6/30/2018
6/30/2017
Revenues      8
Revenue, net 8
Cost of revenue
(Cost of Goods and Services Sold)
    (17)(17)
Gross profit:    (17)(9)
Operating expenses(161,249)(125,703)(60,839)(12,728)(6,917)(7,219)
Other undisclosed operating income586636156 179
Operating loss:(161,249)(125,703)(60,839)(12,728)(6,917)(7,219)
Nonoperating income (expense)4,205(48)1,382(4,590)(2,043)932
Other nonoperating income      932
Interest and debt expense 6,352  (3,774)(6,534) 
Other undisclosed income from continuing operations before equity method investments, income taxes      
Loss from continuing operations:(150,692)(125,752)(59,456)(21,093)(15,495)(6,287)
Loss before gain (loss) on sale of properties:(125,752)(59,456)(21,093)(15,495)(6,287)
Other undisclosed net income    3,774  
Net loss:(150,692)(125,752)(59,456)(17,318)(15,495)(6,287)
Other undisclosed net income (loss) attributable to parent(6,352)   6,534 
Net loss available to common stockholders, diluted:(157,044)(125,752)(59,456)(17,318)(8,961)(6,287)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
6/30/2019
6/30/2018
6/30/2017
Net loss:(150,692)(125,752)(59,456)(17,318)(15,495)(6,287)
Comprehensive loss, net of tax, attributable to parent:(150,692)(125,752)(59,456)(17,318)(15,495)(6,287)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: